Group 5D: HR+ Breast Cancer; Targeted Therapies; Clinical Trials

Poster #1057: Sequential use of PI3K/AKT/mTOR pathway inhibitors alpelisib and everolimus in patients with hormone receptor-positive (HR+) metastatic breast cancer.

Poster #1069: Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study.

Date

Jun 13 2024

Time

2:00 pm - 3:30 pm

Zoom Webinar

REGISTER